Castle biosciences stock.

Oct 31, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 7.52% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ... The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …Castle Biosciences Inc Stock Earnings The value each CSTL share was expected to gain vs. the value that each CSTL share actually gained. CSTL ( CSTL ) reported Q3 2023 earnings per share (EPS) of -$0.26 , beating estimates of -$0.76 by 66.32% .Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …

The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of …

Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.

In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...Secrets and treasures of the ancient world are scattered all across the globe. One of the most incredible discoveries in the history of exploring the ancient world was recently unearthed completely by accident.Oct 25, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...

AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...

6 hours ago · Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.

AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2023. “Castle delivered a strong start to the year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.What exchange does Castle Biosciences trade on and what is the company’s stock symbol? Castle Biosciences’ stock is traded on The Nasdaq Global Market under the ticker symbol "CSTL". It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States. Stock ...

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.thefly.com — Castle Biosciences raises FY23 revenue view to at least $200M, consensus $187.1M News • Nov 1, 2023 GamesIndustry.biz — Remedy posts flat revenue for Q3 2023Castle Biosciences to Participate in Upcoming Investor Conferences. FRIENDSWOOD, Texas-- (BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle …The estimated Net Worth of Mara G. Aspinall is at least $1.28 million dollars as of 2 June 2023. Ms. Aspinall owns over 3,825 units of Castle Biosciences stock worth over $485,681 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.Jul 7, 2023 · In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00. Below is ... The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 6.59% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $17.08 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to date ...

Nov 29, 2023 · The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86. During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35. The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks. Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. Castle will pay an initial $65 million, including $32.5 million in cash, debt, transaction expenses and working capital, as well as $32.5 million in Castle common stock.Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513Ratings analysis incomplete due to data availability. Recommendations not provided. Maximize Income Goal. See Best High Dividend Stocks Model Portfolio for our ...Nov 30, 2023 · A high-level overview of Castle Biosciences, Inc. (CSTL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Tobin Juvenal CSTL stock SEC Form 4 insiders trading. Tobin has made over 5 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently Tobin exercised 6,173 units of CSTL stock worth $14,753 on 1 March 2023.6,173 units of CSTL stock worth $14,753 on 1 March 2023.

Castle Biosciences Today's Change (-0.50%) -$0.10 Current Price $19.78 Key Data Points Market Cap $535M Day's Range $19.62 - $19.95 52wk Range $9.26 - …

11/08/2023 - 01:00 PM. FRIENDSWOOD, Texas -- (BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this …

What exchange does Castle Biosciences trade on and what is the company’s stock symbol? Castle Biosciences’ stock is traded on The Nasdaq Global Market under the ticker symbol "CSTL". Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ...The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...Nov 24, 2023 · Castle Biosciences Inc CSTL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …A stay in one of the world’s most beautiful castle hotels is truly a once-in-a-lifetime experience. These days, you don’t have to be born a royal to live like one, which is why we’ve rounded up some of the best castles in the world that you...Castle Biosciences Inc Registered Shs's market capitalization is $534.59 M by 26.91 M shares outstanding. Castle Biosciences Stock Snapshot 16.00The estimated net worth of Daniel Bradbury is at least $1.27 million as of November 20th, 2023. Mr. Bradbury owns 63,885 shares of Castle Biosciences stock worth more than $1,270,034 as of November 24th. This net worth evaluation does not reflect any other assets that Mr. Bradbury may own. Learn More about Daniel Bradbury's net worth.Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone.

The estimated Net Worth of Frank Stokes is at least $2.05 Million dollars as of 4 April 2023. Mr. Stokes owns over 4,000 units of Castle Biosciences stock worth over $556,435 and over the last 3 years he sold CSTL stock worth over $0. In addition, he makes $1,498,230 as Chief Financial Officer at Castle Biosciences.Nov 24, 2023 · Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...Instagram:https://instagram. is ninjatrader a brokerrare american quarteratlanta braves stock symbolelcr stock The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. plug power inc stock pricee trade transfer stock to another person Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences … stock yinn In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...